Cognitive impairment in Parkinson's disease

Primary Psychiatry

Volumn 12, Issue 7, 2005, Pages 50-55

  Bassett, Susan Spear ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; GALANTAMINE; LEVODOPA; MEMANTINE; MODAFINIL; PRAMIPEXOLE; RIVASTIGMINE;

BRADYKINESIA; BRAIN REGION; COGNITIVE DEFECT; CONCENTRATION RESPONSE; DEGENERATIVE DISEASE; DEMENTIA; FAMILY; FRONTAL CORTEX; HUMAN; MOTOR DYSFUNCTION; PARKINSON DISEASE; PATIENT EDUCATION; PROBLEM SOLVING; REVIEW; TASK PERFORMANCE; TREMOR;

EID: 22544445827     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (83)

1. Parkinson J. An Essay on the Shaking Palsy. London, UK: Sherwood, Neely, and Jones; 1817.
2. Goldman WP, Baty JD, Buckles VD, et al. Cognitive and motor functioning in Parkinson disease: subjects with and without questionable dementia. Arch Neurol. 1998;55(5):674-680.
3. Lees AJ, Smith E. Cognitive deficits in the early stages of Parkinsons disease. Brain. 1983;106(pt 2):257-270.
4. Cooper JA, Sagar HJ, Jordan N, Harvey NS, Sullivan EV. Cognitive impairment in early, untreated Parkinsons disease and its relationship to motor disability. Brain. 1991;114(pt 5):2095-2122.
5. Cooper JA, Sagar HJ, Doherty SM, et al. Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinsons disease. A follow-up study of untreated patients. Brain. 1992;115(pt 6):1701-1725.
6. Levin BE, Katzen HL. Early cognitive changes and nondementing behavioral abnormalities in Parkinsons disease. Adv Neurol. 1995;65:85-95.
7. Zgaljardic DJ, Borod JC, Foldi NS, Mattis P. A review of the cognitive and behavioral sequelae of Parkinsons disease: relationship to frontostriatal circuitry. Cogn Behav Neurol. 2003;16(4):193-210.
8. Higginson CI, King DS, Levine D, et al. The relationship between executive function and verbal memory in Parkinsons disease. Brain Cogn. 2003;52(3):343-352.
9. Green J, McDonald WM, Vitek JL, et al. Cognitive impairments in advanced PD without dementia. Neurology. 2002;59(9):1320-1324.
10. Farina E, Cappa SF, Polimeni M, et al. Frontal dysfunction in early Parkinson's disease. Acta Neurol Scand. 1994;90(1):34-38.
11. Sullivan EV, Sagar HJ, Gabrieli JD, Corkin S, Growdon JH. Different cognitive profiles on standard behavioral tests in Parkinson's disease and Alzheimer's disease. J Clin Exp Neuropsychol. 1989;11(6):799-820.
12. Locascio JJ, Corkin S, Growdon JH. Relation between clinical characteristics of Parkinson's disease and cognitive decline. J Clin Exp Neuropsychol. 2003;25(1):94-109.
13. Smith MC, Goldman WP, Janer KW, Baty JD, Morris JC. Cognitive speed in nondemented Parkinson's disease. J Int Neuropsychol Soc. 1998;4(6):584-592.
14. Berry EL, Nicolson RI, Foster JK, Behrmann M, Sagar HJ. Slowing of reaction time in Parkinson's disease: the involvement of the frontal lobes. Neuropsychologia. 1999;37(7):787-795.
15. Azuma T, Cruz RF, Bayles KA, Tomoeda CK, Montgomery EB Jr. A longitudinal study of neuropsychological change in individuals with Parkinson's disease. Int J Geriatr Psychiatry. 2003;18(11):1043-1049.
16. Janvin C, Aarsland D, Larsen JP, Hugdahl K. Neuropsychological profile of patients with Parkinson's disease without dementia. Dement Geriatr Cogn Disord. 2003;15(3):126-131.
17. Pollock M, Hornabrook RW. The prevalence, natural history and dementia of Parkinson's disease. Brain. 1966;89(3):429-448.
18. Boller F. Mental status of patients with Parkinson's disease. J Clin Neurophysiol. 1980;2:157-172.
19. Martin WE, Loewenson RB, Resch JA, Baker AB. Parkinson's disease. Clinical analysis of 100 patients. Neurology. 1973;23(8):783-790.
20. Pirozzolo FJ, Hansch EC, Mortimer JA, Webster DD, Kuskowski MA. Dementia in Parkinson disease: a neuropsychological analysis. Brain Cogn. 1982;1(1):71-83.
21. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol. 2003;60(3):387-392.
22. Woods SP, Troster AI. Prodromal frontal/executive dysfunction predicts incident dementia in Parkinson's disease. J Int Neuropsychol Soc. 2003;9(1):17-24.
23. Levy G, Jacobs DM, Tang MX, et al. Memory and executive function impairment predict dementia in Parkinson's disease. Mov Disord. 2002;17(6):1221-1226.
24. Mahieux F, Fenelon G, Flahault A, et al. Neuropsychological prediction of dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry. 1998;64(2):178-183.
25. Levy G, Tang MX, Cote LJ, et al. Motor impairment in PD: relationship to incident dementia and age. Neurology. 2000;55(4):539-544.
26. Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci. 1986;9:357-381.
27. Wichmann T, DeLong MR. Functional and pathophysiological models of the basal ganglia. Curr Opin Neurobiol. 1996;6(6):751-758.
28. Thiel A, Hilker R, Kessler J, Habedank B, Herholz K, Heiss WD. Activation of basal ganglia loops in idiopathic Parkinson's disease: a PET study. J Neural Transm. 2003;110(11):1289-1301.
29. Werheid K, Zysset S, Muller A, Reuter M, von Cramon DY. Rule learning in a serial reaction time task: an fMRI study on patients with early Parkinson's disease. Brain Res Cogn Brain Res. 2003;15(2):273-284.
30. Emre M. What causes mental dysfunction in Parkinson's disease? Mov Disord. 2003;18(suppl 6):S63-S71.
31. Riekkinen P Jr, Kejonen K, Laakso MP, Soininen H, Partanen K, Riekkinen M. Hippocampal atrophy is related to impaired memory, but not frontal functions in non-demented Parkinson's disease patients. Neuroreport. 1998;9(7):1507-1511.
32. Camicioli RM, Korzan JR, Foster SL, et al. Posterior cingulate metabolic changes occur in Parkinson's disease patients without dementia. Neurosci Lett. 2004;354(3):177-180.
33. Trepanier LL, Saint-Cyr JA, Lozano AM, Lang AE. Neuropsychological consequences of posteroventral pallidotomy for the treatment of Parkinson's disease. Neurology. 1998;51(1):207-215.
34. Alegret M, Valldeoriola F, Tolosa E, et al. Cognitive effects of unilateral posteroventral pallidotomy: a 4-year follow-up study. Mov Disord. 2003;18(31):323-328.
35. Valldeoriola F, Martinez-Rodriguez J, Tolosa E, et al. Four year follow-up study after unilateral pallidotomy in advanced Parkinson's disease. J Neurol. 2002;249(12):1671-1677.
36. Funkiewiez A, Ardouin C, Caputo E, et al. Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2004;75(6):834-839.
37. Morrison CE, Borod JC, Perrine K, et al. Neuropsychological functioning following bilateral subthalamic nucleus stimulation in Parkinson's disease. Arch Clin Neuropsychol. 2004;19(2):165-181.
38. Daniele A, Albanese A, Contarino MF, et al. Cognitive and behavioural effects of chronic stimulation of the subthalamic nucleus in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 2003;74(2):175-182.
39. Carbon M, Ghilardi MF, Feigin A, et al. Learning networks in health and Parkinson's disease: reproducibility and treatment effects. Hum Brain Mapp. 2003;19(3):197-211.
40. Marini P, Ramat S, Ginestroni A, Paganini M. Deficit of short-term memory in newly diagnosed untreated parkinsonian patients: reversal after L-dopa therapy. Neurol Sci. 2003;24(3):184-185.
41. Nieoullon A, Coquerel A. Dopamine: a key regulator to adapt action, emotion, motivation and cognition. Curr Opin Neurol. 2003;16(suppl 2):S3-S9.
42. Grossman M, Glosser G, Kalmanson J, Morris J, Stern MB, Hurtig HI. Dopamine supports sentence comprehension in Parkinson's Disease. J Neurol Sci. 2001;184(2):123-130.
43. Kulisevsky J. Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease. Drugs Aging. 2000;16(5):365-379.
44. Growdon JH, Kieburtz K, McDermott MP, Panisset M, Friedman JH, for the Parkinson Study Group. Levodopa improves motor function without impairing cognition in mild non-demented Parkinson's disease patients. Neurology. 1998;50(5):1327-1331.
45. Cools R, Barker RA, Sahakian BJ, Robbins TW. L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinsons disease. Neuropsychologia. 2003;41(11):1431-1441.
46. Marjama-Lyons JM, Koller WC. Parkinsons disease. Update in diagnosis and symptom management. Geriatrics. 2001;56(8):24-35.
47. Brusa L, Bassi A, Stefani A, et al. Pramipexole in comparison to 1-dopa: a neuropsychological study. J Neural Transm. 2003;110(4):373-380.
48. Webster DD. Critical analysis of the disability in Parkinson's disease. Mod Treat. 1968;5(2):257-282.
49. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology. 1967;17(5):427-442.
50. Ilson J, Bressman S, Fahn S. Current concepts in Parkinson's disease. Hosp Med. 1983;19:33.
51. Caparros-Lefebvre D, Pecheux N, Petit V, Duhamel A, Petit H. Which factors predict cognitive decline in Parkinson's disease? J Neurol Neurosurg Psychiatry. 1995;58(1):51-55.
52. Abudi S, Bar-Tal Y, Ziv L, Fish M. Parkinson's disease symptoms-patients' perceptions. J Adv Nurs. 1997;25(1):54-59.
53. Brod M, Mendelsohn GA, Roberts B. Patients' experiences of Parkinson's disease. J Gerontol B Psychol Sci. Soc Sci. 1998;53(4):213-222.
54. Lee KS, Merriman A, Owen A, Chew B, Tan TC. The medical, social, and functional profile of Parkinson's disease patients. Singapore Med J. 1994;35(3):265-268.
55. Hobson P, Holden A, Meara J. Measuring the impact of Parkinson's disease with the Parkinson's Disease Quality of Life questionnaire. Age Ageing. 1999;28(4):341-346.
56. Baron MS, Vitek JL, Bakay RA, et al. Treatment of advanced Parkinson's disease by posterior GPi pallidotomv: 1-year results of a pilot study. Ann Neurol. 1996;40(3):355-366.
57. Block G, Liss C, Reines S, Irr J, Nibbelink D, for the CR First Study Group. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. Eur Neurol. 1997;37(1):23-27.
58. McRae C, O'Brien C, Freed C. Quality of life among persons receiving neural implant surgery for Parkinson's disease. Mov Disord. 1996;11:605-606.
59. Mahieux F, Michelet D, Manifacier MJ, Boller F, Fermanian J, Guillard A. Mini-Mental Parkinson: first validation study of a new bedside test contracted for Parkinson's disease. Behav Neurol. 1995;8:15-22.
60. Jorm AF A short form of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): development and cross-validation. Psychol Med. 1994;24(1):145-153.
61. Erratum in: Psychol Med. 1995;25(2):437.
62. Farias ST, Mungas D, Reed B, Haan MN, Jagust WJ. Everyday functioning in relation to cognitive functioning and neuroimaging in community-dwelling Hispanic and non-Hispanic older adults. J Int Neuropsychol Soc. 2004;10(3):342-354.
63. Pakrasi S, Mukaetova-Ladinska EB, McKeith IG, O'Brien JT. Clinical predictors of response to Acetyl Cholinesterase Inhibitors: experience from routine clinical use in Newcastle. Int J Geriatr Psychiatry. 2003;18(10):879-886.
64. Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry. 2002;72(6):708-712.
65. Erratum in: J Neurol Neurosurg Psychiatry. 2002;73(3):354.
66. Leroi I, Brandt J, Reich SG, et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry. 2004;19(1):1-8.
67. Gabelli C. Rivastigmine: an update on therapeutic efficacy in Alzheimer's disease and other conditions. Curr Med Res Opin. 2003;19(2):69-82.
68. Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov Disord. 2001;16(6):1171-1174.
69. Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinsons disease: a case series. Curr Med Res Opin. 2002;18(5):258-264.
70. Giladi N, Shabtai H, Gurevich T, Benbunan B, Anca M, Korczyn AD. Rivastigmine (Exelon) for dementia in patients with Parkinson's disease. Acta Neurol Scand. 2003;108(5):368-373.
71. Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int J Geriatr Psychiatry. 2003;18(10):937-941.
72. Lemay S, Chouinard S, Blanchet P, et al. Lack of efficacy of a nicotine transdermal treatment on motor and cognitive deficits in Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(1):31-39.
73. Turner DC, Clark L, Dowson J, Robbins TW, Sahakian BJ. Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder. Biol Psychiatry. 2004;55(10):1031-1040.
74. Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002;27(5):699-711.
75. Simpson D, Plosker GL. Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder. CNS Drugs. 2004;18(6):397-401.
76. Rabey JM, Nissipeanu P, Korczyn AD. Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinsons disease. J Neural Transm Park Dis Dement Sect. 1992;4:277-282.
77. Merello M, Nouzeilles MI, Cammarota A, Leiguarda R. Effect of memantine (NMDA antagonist) on Parkinsons disease: a double-blind crossover randomized study. Clin Neuropharmacol. 1999;22(5):273-276.
78. Jarvis B, Figgitt DP. Memantine. Drugs Aging. 2003;20(6):465-476.
79. Lokk J. Memantine can relieve certain symptoms in Parkinson disease. Improvement achieved in two out of three described cases with dyskinesia and cognitive failure [in Swedish]. Lakartidningen. 2004;101(23):2003-2006.
80. Trend P, Kaye J, Gage H, Owen C, Wade D. Short-term effectiveness of intensive multidisciplinary rehabilitation for people with Parkinson's disease and their carers. Clin Rehabil. 2002;16(7):717-725.
81. Wade DT, Gage H, Owen C, Trend P, Grossmith C, Kaye J. Multidisciplinary rehabilitation for people with Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry. 2003;74(2):158-162.
82. Loewenstein DA, Acevedo A, Czaja SJ, Duara R. Cognitive rehabilitation of mildly impaired Alzheimer disease patients on cholinesterase inhibitors. Am J Geriatr Psychiatry. 2004;12(4):395-402.
83. van Spaendonck KP, Berger HJ, Horstink MW, Borm GF, Cools AR. Memory performance under varying cueing conditions in patients with Parkinson's disease. Neuropsychologia. 1996;34(12):1159-1164.